Insider Trading Arrangements

3 Months Ended

Dec. 31, 2025

OTHER INFORMATION

During the three months ended December 31, 2025, no director or officer of the company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as provided below.

Name & Title

Action Taken

Date Adopted

Type of Trading Arrangement (1)

Aggregate Number of Shares to be Sold Pursuant to Trading Arrangement (2)

Duration of Trading Arrangement(3)

Perry C. Siatis

Executive Vice President,
General Counsel and
Secretary

Adoption

11/18/2025

Rule 10b5-1 Trading Arrangement

Up to 41,049 Shares to be Sold

11/18/2026

1. Except as indicated by footnote, each trading arrangement marked as a "Rule 10b5-1 Trading Arrangement" is intended to satisfy the affirmative defense of Rule 10b5-1(c), as amended.

2. The number of shares to be sold under each trading arrangement includes the maximum actual number of shares issuable under the applicable performance stock awards. The actual number of shares to be sold under the performance stock awards will depend on the achievement of applicable performance conditions under the awards and the number of shares withheld to satisfy tax obligations upon the vesting of the awards.

3. Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all sales or (b) the date listed in the table. Each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” only permitted or only permits transactions upon expiration of the applicable mandatory cooling-off period under the Rule.

Non-Rule 10b5-1 Arrangement Adopted

false

Rule 10b5-1 Arrangement Terminated

false

Non-Rule 10b5-1 Arrangement Terminated

false

Perry C. Siatis [Member]

Trading Arrangements, by Individual

Name

Perry C. Siatis

Title

Executive Vice President,General Counsel and Secretary

AbbVie Inc. 10-K